Fibroblasts From Type 1 Diabetics Exhibit Enhanced Ca$^{2+}$ Mobilization after TNF or Fat Exposure

Nicholas R. Husni*, Albert R. Jones IV, Amber L. Simmons, Barbara E. Corkey*

Obesity Research Center, Evans Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America

Abstract

The effects of cytokine and fatty acid treatment on signal transduction in dermal fibroblasts from type 1 diabetics and matched controls were compared. Chronic exposure to TNF, accentuated Ca$^{2+}$ mobilization in response to bradykinin (BK) in cells from both controls and diabetics; responses were three-fold greater in cells from diabetics than in controls. Similarly, with chronic exposure to IL-1β, BK-induced Ca$^{2+}$ mobilization was accentuated in cells from type 1 diabetics compared to the controls. Pretreatment with the protein synthesis inhibitor cycloheximide or the protein kinase C inhibitor calphostin C prior to the addition of TNF completely abrogated the TNF-induced increment in peak bradykinin response. Ca$^{2+}$ transients induced by depleting endoplasmic reticulum (ER) Ca$^{2+}$ with thapsigargin were also greater in TNF treated fibroblasts than in untreated cells, with greater increases in cells from diabetics. Exposing fibroblasts for 48 hours to 2 mM oleate also increased both the peak bradykinin response and the TNF-induced increment in peak response, which were significantly greater in diabetics than controls. These data indicate that cells from diabetic patients acquire elevated ER Ca$^{2+}$ stores in response to both cytokines and free fatty acids, and thus exhibit greater sensitivity to environmental inflammatory stimuli and elevated lipids.

Citation: Husni NR, Jones IV AR, Simmons AL, Corkey BE (2014) Fibroblasts From Type 1 Diabetics Exhibit Enhanced Ca$^{2+}$ Mobilization after TNF or Fat Exposure. PloS ONE 9(1): e87068. doi:10.1371/journal.pone.0087068

Editor: Rasheed Ahmad, Dasman Diabetes Institute, Kuwait

Received September 22, 2013; Accepted December 24, 2013; Published January 23, 2014

Copyright: © 2014 Husni et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by NIH PO1 DK46200, JDRF # Juvenile Diabetes Foundation (Grant #198230); and Zoltan Kohn endowment to BEC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.
* E-mail: bcorkey@bu.edu
** Current address: Gates Mills, United States of America

Introduction

The inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β) are implicated in both type 1 and type 2 diabetes [1]. Elevated levels of these cytokines occur in newly diagnosed type 1 diabetics and in spontaneously diabetic mice [2–4]. Increased serum levels of TNF are also detected throughout the lives of both type 1 and type 2 diabetic patients [3] and in response to viral infection [5]. TNF and IL-1β impair glucose-stimulated insulin secretion [6], are directly toxic to pancreatic β-cells, and are implicated in autoimmune islet cell destruction [7,8].

Despite abundant research, the etiology of type 1 diabetes remains unknown, however, there is support for a viral trigger for the disease [9]. Although debate continues concerning the nature of such a virus, abundant evidence links prior viremia and the onset of type 1 diabetes [10]. TNF is a pluripotent cytokine, producing effects on cells that range from the extremes of proliferation to apoptosis [11–14]. TNF initiates its cellular effects by binding to one of its two cell surface receptors: receptor p75 is involved in cell death signals and receptor p55 mediates activation of several intracellular signaling pathways including protein kinase C (PKC), phospholipase A$_2$ (PLA$_2$), mitogen activated protein kinase, and sphingomyelinase/ceramide [11–15]. IL-1β signaling has been shown to largely overlap the pathways used by TNF, and the two cytokines have many of the same effects on cells despite the fact that they bind to different plasma membrane receptors. Treatment of cells with TNF and IL-1β results in a strikingly similar pattern of phosphorylation and dephosphorylation, varying greatly from phosphorylation patterns obtained following treatment with another cytokine, epidermal growth factor [16].

Although type 1 diabetic patients may also have elevated serum levels of free fatty acids (FFA) or triglyceride, much less is known about how this may contribute to diabetic pathology than is known about the hyperglycemia-related pathologies. Even in non-ketotic states, type 1 diabetics have dyslipidemia, or elevated levels of FFA in serum [17]. Following insulin-induced hypoglycemia, stimulation of type 1 diabetics with epinephrine results in increases in FFA greater than in controls subjected to the same maneuver [18,19]. Short term ketosis in type 1 diabetes is associated with almost doubled plasma FFA concentrations [20]. In addition to these few studies in type 1 diabetics, certain FFA have been shown to have effects on non-diabetic cells, ranging from modulation of intracellular Ca$^{2+}$ homeostasis [21,22] to activation of the nuclear transcription factor NF-κB and alteration of gene expression [23,24]. Elevated plasma FFA, particularly saturated FFA, have been shown to induce islet inflammation [25]. Elevated extracellular FFA results in increased cytosolic long chain CoA, the effects of which may include modulating PKC activity, intracellular protein trafficking, G-protein activity, endoplasmic reticulum (ER) Ca$^{2+}$-ATPase activity, expression of acetyl-CoA carboxylase, and peroxisome proliferation [24,26,27].
Inflammatory cytokines also affect lipid synthesis and metabolism. In rat liver, TNF increases hepatic fatty acid synthesis and lipid secretion [28–30]. Within 90 minutes, TNF treatment causes increases in hepatic citrate levels. The rise in citrate should elevate cytosolic long chain acyl CoA levels because citrate activates acetyl-CoA carboxylase which converts acetyl-CoA to malonyl-CoA, and since malonyl CoA is an inhibitor of carnitine palmitoyl transferase 1, the transporter that moves long chain acyl-CoA into the mitochondria for oxidation. Endotoxin inhibits oxidation of FFA in rats: it is presumed that this effect is mediated through TNF and IL-1β (endotoxin is a potent stimulator of TNF and IL-1β production by macrophages, which are known to mediate many endotoxin effects) [31]. TNF can also increase cytosolic FFA content directly, by activating phospholipase A2 [13,32,33].

Bradykinin (BK) is a vasodilator that plays a role in the inflammatory process, mediating acute responses to injury such as vasodilation, edema, and pain. Binding of BK to the G-protein coupled B2 receptor subtype leads to the activation of the phospholipase-C/inositol 1,4,5-trisphosphate (IP3) cascade and subsequent release of Ca^{2+} from internal stores [34–36]. The B2 receptor pathway also leads to an acute burst of prostaglandin E2 production in fibroblasts [37]. TNF and IL-1β have been shown to
potentiate BK responsiveness in varied experimental systems [38,39]. BK is an effective receptor-mediated agonist that we used in our studies to mobilize intracellular Ca\(^{2+}\).

The focus of this work was to compare the effects of inflammatory cytokines and fatty acids on BK-induced Ca\(^{2+}\) mobilization in fibroblasts from people with and without type 1 diabetes. The hypothesis examined was that type 1 diabetics have altered cytokine-mediated signaling compared to controls. Altered cytokine sensitivity in type 1 diabetics could clarify one role that inflammatory cytokines play in the pathogenesis of insulitis and induction of autoimmune \(\beta\)-cell destruction. We show here that TNF treatment of fibroblasts from diabetic subjects increased Ca\(^{2+}\) responses to BK about threefold above control values and that relatives of patients exhibited intermediate responses. Our data also show a significant differences between control and type 1 diabetic fibroblasts in Ca\(^{2+}\) signaling following FFA treatment.

Research Design and Methods

Ethics Statement

This research meets all applicable standards for the ethics of experimentation and research integrity. This research involved no active patient participation. The authors had no contact or interaction with the donors therefore no consent was required. Because human tissue samples were obtained through a third party vendor (The Coriell Institute for Medical Research, Camden, NJ), our research was exempt from the Boston University Institutional Review Board (H25457). The Coriell Institute ensured compliance with DHHS regulations for the protection of human subjects (45CFR Part 46). Human tissue was handled solely by the authors of this paper in our country of residence.

Cell Cultures

Dermal fibroblasts were obtained from the Coriell Institute for Medical Research, Camden, NJ. Fibroblasts were obtained from 7
apparently normal donors, 10 donors identified as type 1 diabetics, and 3 non-diabetic siblings of the diabetic donors. Diabetic donors were matched to controls based on age, gender and race.

Fibroblast Growth and Preparation
Cells were grown in Minimal Essential Medium (MEM) with Earle’s salts, 2X concentration of essential and non-essential amino acids for MEM, 1X antibiotic/antimycotic, and 20% fetal bovine serum (FBS) from Hyclone Laboratories, Inc. (Logan, UT). All other cell culture solutions were purchased from Gibco Life Technologies (Gaithersburg, MD). Upon confluence, cells were removed from culture flasks by incubating for 1 minute in 0.7 mM EDTA in Dulbecco’s phosphate buffered saline (PBS; pH 7.4), and then for 2–5 minutes in 0.25% trypsin. Cells were then washed with PBS/EDTA and used for experiments, or passaged in a ratio appropriate to the culture’s growth rate.

Cell Treatments
All experiments were performed in serum free media. Unless otherwise noted, the concentrations of TNF and IL-1β (both purchased from Genzyme Corporation, Cambridge, MA) were 10 ng/ml (0.6 nM) and 1 ng/ml (0.06 nM), respectively. The exposure to cytokine treatment was 24 hours (unless otherwise indicated) before cells were removed for Ca2+ measurement, which was performed in the absence of cytokines. Cells were preincubated for 30 minutes with 20 μM indomethacin (Sigma Chemical Company, St. Louis, MO) and 100 nM Calphestin C (Calbiochem-Novabiochem International, La Jolla, CA) prior to the addition of TNF. Cycloheximide (3 μg/ml; Sigma) was preincubated for 3 hours before the addition of cytokines. Glucose (6 or 11 mM final) and oleic acid (2 mM; Sigma) were preincubated for 24 hours before cytokine addition. Oleic acid (free acid) was prepared as a stock solution of 0.1 M in NaOH (pH 9), and complexed to 2% fatty acid free bovine serum albumin (BSA; Sigma) at a final concentration of 2 mM.

As all fibroblast cultures were grown and maintained in a medium containing 20% FBS, and all TNF treatments were done in serum free medium, a preliminary experiment was performed in order to confirm that our TNF solution was not simply replacing a serum component in otherwise serum-starved cells. The addition of FBS did not cause a significant change in peak bradykinin response above those not treated with FBS.

Ca2+ Measurement
Cytosolic free Ca2+ was determined from changes in the excitation signals of the fluorescent indicator fura-2 at 340 and 380 nm, measuring emission at 510 nm, using a Hitachi F-2000 fluorescence spectrophotometer, as described previously [40] (Hitachi High Technologies Corp., Tokyo, Japan). Following trypsinization and washing with PBS/EDTA, fibroblasts were loaded with 1 μM fura-2-ace toxyethyl (AM) ester (Molecular Probes, Eugene, OR) in MEM culture medium containing 0.5% BSA for 15 minutes. Approximately 250,000 cells were suspended in modified Krebs-HEPES buffer containing 120 mM NaCl, 5 mM KCl, 5 mM NaHCO3, 2 mM CaCl2, 1 mM MgCl2, 1 mM Na2HPO4, 10 mM glucose, 10 mM HEPES, 0.05% BSA, and 10 μM sulfinpyrazone (to block active extrusion of the fura), pH 7.4. The maximum Ca2+/fura-2 and minimum free fura-2 signals were determined after addition of Triton X-100 to equilibrate Ca2+ across the plasma membrane. The minimum Ca2+/fura-2 and maximum free fura-2 signals were determined after addition of EGTA (plus Tris buffer to maintain pH). The cytosolic free Ca2+ concentration was calculated by measuring the 2 fura signals as a percentage of the maxima where the Kd is 225 nM as described previously [40]. Ca2+ transients were measured in suspensions of confluent fibroblasts between passages 7 and 30; no
consistent passage-dependent variation in the responsiveness of the cells was observed over this range.

**Permeabilized Cell System**

After detaching with trypsin/EDTA as described, cells were resuspended in a buffer containing 100 mM KCl, 22 mM NaCl, 5 mM KHCO₃, 20 mM HEPES, 1 mM MgCl₂, 6 mM KH₂PO₄, 4 mM MgATP, 12 mM creatine plus creatine phosphate, 30 μg/ml creatine phosphokinase, and 1 μM fura-2 free acid [21]. Antimycin A (0.2 μg/ml) and oligomycin (2 μg/ml) were added to inhibit mitochondrial Ca²⁺ uptake. Saponin (60 μg/ml) was added when indicated to permeabilize the cells. The Ca²⁺ concentration in the buffer was measured by the fluorescence of free fura-2 (1 μM).

**Analysis of Data**

To determine statistical differences between groups, analysis of variance (ANOVA) was used with Tukey’s post-hoc test for comparison of independent groups when appropriate (unless otherwise noted). Error bars on the figures represent the standard error of the mean.

**Results**

**TNF and IL-1β Altered BK Responses in Fibroblasts from Control and Diabetic Donors**

TNF treatment had neither an acute effect on human fibroblasts on Ca²⁺ levels nor on BK-induced Ca²⁺ mobilization (data not shown). Figure 1A shows a representative trace that illustrates the raw data obtained and the pattern of TNF (0.6 nM)-potentiated BK-induced Ca²⁺ mobilization (compare heavy line (treated) with fine line (untreated)). This figure shows representative traces from control and diabetic donors. In both control and diabetic donors, TNF treatment augmented BK-induced Ca²⁺ mobilization, although to a much greater extent in the diabetic donor (right panel). Similar sensitivity of diabetic donors were seen with 24 hours of IL-1β treatment (60 fM). Figure 1B shows representative traces in fibroblasts from control and diabetic donors in which IL-1β, like TNF, caused a greater increase in peak BK response in the diabetic donor whereas the response of the control was greater without treatment and not affected by IL-1β. These illustrations suggest that the enhanced cytokine sensitivity observed in diabetic fibroblast responses may not be limited to...
TNF but may reflect a general response to cytokines. However, further experiments were done with only TNF.

**Time and Concentration Dependence of TNF Treatment to Affect BK-induced Ca\(^{2+}\) Mobilization**

To determine the optimal time required for TNF to induce the peak BK response, time course series were performed in fibroblasts from 3 different donors, in which the cells were treated with 0.6 nM TNF for 1, 2, 4, 12, 24, or 48 hr. Figure 2A shows the results of these experiments; each bar on the graph represents the mean of 2 to 6 separate determinations. In these donors, a TNF-induced increment in peak BK response could be seen within a few hours of treatment. A maximum increment was achieved by 24 hr that did not diminish significantly by 48 hr of treatment. All further incubations were for 24 hr.

The observation that time was required for TNF treatment to induce a change in peak BK response in fibroblasts (Figure 2A) suggested that the BK response might be dependent on the synthesis of new proteins. Cycloheximide, an inhibitor of protein synthesis, was employed to determine if synthesis was required for TNF to have its effect. There was no effect of TNF on fibroblasts pre-treated with cycloheximide indicating that expression of new proteins was needed for the observed effect (data not shown).

Evaluation of the concentration dependence of the stimulatory effect of TNF on the BK response (Figure 2B) indicated that the peak response occurred between 0.1 and 1 nM. Further experiments were performed at 0.6 nM TNF based on this experiment.

**Ca\(^{2+}\) Responses to BK in Control and Diabetic Fibroblasts: Effect of TNF Treatment**

The concentration for maximal BK responses was tested between 0 and 10 \(\mu\)M and data are summarized in Figure 3. The concentration of BK where peak responses occurred were not altered by TNF in either control or diabetic cells. Subsequent experiments were performed with 1 \(\mu\)M BK.

Figure 5. Representative traces to determine the source of TNF-induced increases in Ca\(^{2+}\) in response to BK. A. Untreated and TNF-treated (0.6 nM for 24 hours) fibroblasts were exposed to 200 nM BK. Addition of 2 mM EGTA 10 seconds prior to BK stimulation did not affect the magnitude of the peak in either untreated or TNF-treated cells, but did eliminate the increase in final Ca\(^{2+}\) equilibrium. These are representative traces from one diabetic donor. B. Fura loaded fibroblasts (untreated and TNF treated) from one control and one type 1 diabetic donor were treated with 30 nM thapsigargin at 170 seconds to release Ca\(^{2+}\) from the endoplasmic reticulum stores. These experiments were repeated three times with similar results.

doi:10.1371/journal.pone.0087068.g005
Figure 6. Representative trace illustrating the Ca²⁺ set point in permeabilized fibroblasts. Untreated and TNF-treated (0.6 nM for 24 hours) fibroblasts were suspended in an intracellular buffer containing 1 μM fura-2 free acid, and permeabilized with saponin (60 μg/ml) at 100 seconds. The cells took up Ca²⁺ from the buffer until steady state was reached. These experiments were repeated three times with similar results. doi:10.1371/journal.pone.0087068.g006

Figure 7. Representative traces of the effect of oleate and oleate plus TNF on peak BK response in fibroblasts from a single type 1 diabetic donor. These are representative traces of BK responses in fibroblasts from a single diabetic donor. Where indicated, 2 mM oleic acid was added 24 hours before, and throughout the subsequent 24 hour incubation. Cells in basal 5.6 mM glucose were treated with TNF, loaded with fura, and tested with BK as described in Figure 1. doi:10.1371/journal.pone.0087068.g007
A major difference between control and diabetic cells can be seen clearly from the average TNF-induced increment in peak BK response that exceeded 100 nM in all subjects (Figure 3A). However, cells from donors with diabetes showed a striking 3-fold greater effect of TNF than control cells (Figure 3A, black bars).

Because of the important signal transducing properties of the sustained phase of the Ca\(^{2+}\) response, the effects of TNF treatment on the increment in steady state, or final equilibration, caused by BK were examined (Figure 3B). TNF pre-treatment also caused significant elevations in steady state Ca\(^{2+}\) during the sustained phase of the BK response in both control and diabetic donors which was significantly higher in the TNF pretreated diabetic fibroblasts than in the controls (\(p<0.005\), Figure 3B).

Comparison of BK Responses of Type 1 Diabetic, Non-diabetic Siblings of Diabetics and Controls
The pathogenesis of type 1 diabetes indicates that there is a strong genetic component to the disease [41]. Cells from three non-diabetic siblings of the 10 previously described diabetic donors (all three from different families) were obtained to determine whether the fibroblasts from the non-diabetic siblings more closely resembled diabetics, or controls without a family history of diabetes. Figure 4 shows the TNF-induced increment in peak BK response in the 7 original control donors and the 10 original diabetic donors, plus 3 non-diabetic siblings of the diabetic donors. Interestingly, cells from donors whose siblings are diabetic exhibited a response that fell in between that of cells from donors with vs. without diabetes (\(p<0.001\) between any group). This intermediate Ca\(^{2+}\) response to bradykinin from siblings of diabetics suggests that Ca\(^{2+}\) mobilization can be altered even in the presence of apparently healthy insulin response to glucose.

Basal Ca\(^{2+}\) in Control and Diabetic Fibroblasts: Effect of TNF Treatment
The effect of TNF treatment on basal Ca\(^{2+}\) was determined in fibroblasts from 7 control and 10 diabetic donors (a mean of 96 to 105 separate determinations). In control donors, TNF did not significantly affect basal Ca\(^{2+}\) concentrations (71±2 nM pre- vs 74±2 nM post- 24 h TNF). In donors with diabetes, basal Ca\(^{2+}\) was lower initially and was increased by TNF from 60±2 nM to 80±4 nM (\(p<0.05\)) (Figure 3B).

Figure 8. The effect of oleate and TNF on peak BK response in human fibroblasts. Fibroblasts from 3 relatively unresponsive controls and 4 diabetic donors were used. Where indicated, 2 mM oleic acid and/or TNF was added 24 hours before, and throughout the subsequent 24 hour incubation. Cells were then loaded with fura and tested with BK as described in Figure 1. Data are expressed here as a percentage of the untreated condition (5.6 mM glucose). A. Both TNF and oleic acid had significant effects on peak BK response in diabetic cells (ANOVA \(p<0.05\) and \(p<0.001\) respectively). B. Oleic acid had a significant effect on the sustained steady state Ca\(^{2+}\) (\(p<0.001\)) in diabetic fibroblasts (\(p<0.001\)).

doi:10.1371/journal.pone.0087068.g008
70 ± 3 nM (p < 0.001). Before treatment differences between fibroblasts from donors with and without diabetes were statistically significant (p < 0.001).

**TNF Increased the Endoplasmic Reticulum (ER) Ca^{2+} Pool by Facilitating Influx**

To determine whether the TNF-induced increase in the peak BK response was due to mobilization of Ca^{2+} from intracellular stores or extracellular Ca^{2+} uptake, the Ca^{2+} chelator EGTA was added to the extracellular media immediately prior to stimulation with BK. The peak response to bradykinin was unaltered in the presence of EGTA chelation of extracellular Ca^{2+} in both untreated cells and TNF-treated cells (Figure 5A). This indicated that extracellular Ca^{2+} did not contribute to the bradykinin-induced peak Ca^{2+} response. The sustained elevation in steady state Ca^{2+} normally seen following bradykinin stimulation was abrogated both in untreated and TNF treated cells. Presumably the sustained phase was due to entry of extracellular Ca^{2+}.

Thapsigargin, an irreversible inhibitor of the ER Ca^{2+}-ATPase which depletes ER Ca^{2+} stores by inhibiting Ca^{2+} transport into the ER, was used to determine if the size of the ER Ca^{2+} pool influenced the TNF-induced increment in peak BK response. Addition of thapsigargin released Ca^{2+} from the ER, resulting in a rapid transient rise of cytosolic Ca^{2+} (Figure 5B). In fibroblasts from both control and diabetic donors, thapsigargin-induced Ca^{2+} peaks were greater following TNF treatment compared to cells that were not treated indicating that TNF treatment increased the ER Ca^{2+} stores (Figure 5B). As with bradykinin-induced Ca^{2+} mobilization (Figure 2A), the difference between the peak Ca^{2+} concentration between TNF-treated and untreated was much larger in the cells from patients with type 1 diabetes (394 ± 28) compared to the controls (127 ± 20, p = 0.001).

The ER Ca^{2+}-ATPase regulates Ca^{2+} entry and, consequently, the size of the ER Ca^{2+} pools. To determine if the activity of the ER Ca^{2+}-ATPase was affected by TNF treatment, fibroblasts were suspended in a buffer mimicking intracellular ion concentrations with no added Ca^{2+} and 1 μM fura-2 free acid (a fluorescent dye that fluoresces when it binds free Ca^{2+}), and permeabilized with the detergent, saponin. The inhibitors oligomycin and antimycin A were added in order to inhibit the transport of Ca^{2+} into the mitochondria and limit the uptake of Ca^{2+} to the ER. As expected, the addition of saponin resulted in permeabilization of the cells and consequent rapid uptake of Ca^{2+} into the stores (Figure 6). The cells treated with TNF reached equilibrium faster, and the final equilibrium reached was lower. This suggested that TNF promoted Ca^{2+} transport into the ER via the Ca^{2+}-ATPase.

Changes in calreticulin binding have been shown to modulate the responses of Ca^{2+} mobilizing agonists [42], such that an increase in calreticulin levels could cause an increase in the size of the Ca^{2+} stores; however, western blot analysis showed no change in calreticulin levels after 24 hours of TNF treatment and there was no difference in calreticulin expression between control and diabetic fibroblasts (data not shown).

**Effects of Free Fatty Acids on Ca^{2+} Signaling**

The diabetic phenotype is associated with elevated blood glucose and lipid concentrations [43]. Circulating levels of FFA can impact cellular signaling and have the potential to affect Ca^{2+} mobilization. To examine the effects of FFA on BK-induced Ca^{2+}
mobilization and on the TNF-induced increment, fibroblasts from 4 diabetic and 3 control donors were treated with 2 mM oleate for 48 hours. The fibroblasts from control donors were specifically selected from our collection of fibroblasts because they had responded to TNF treatment with only modest increases in peak BK response and steady state Ca\(^{2+}\) levels. The addition of fatty acids increased Ca\(^{2+}\) mobilization; simultaneous treatment of TNF and oleate led to the greatest effect. Figure 7 illustrates an experiment performed on fibroblasts from a single diabetic donor. As can be seen from the superimposed traces, each of the treatments had an effect on both peak BK response and the sustained plateau phase of the response following recovery from the peak. Traces from control donors showed little effect of TNF and a small effect of the diabetic medium.

A summary of the results of experiments performed in 3 control and 4 diabetic donors is shown in Figure 8. Since there was some variation among donors, peak responses to BK were normalized to a percentage of that obtained with the control glucose alone. In addition, because FFA are added complexed to BSA it was necessary to add the same concentration of BSA to the control cells, however, the 2% BSA used in the media also binds a portion of the TNF. This may explain the failure of the control fibroblasts to respond to TNF treatment and the smaller response in the diabetic fibroblasts, in contrast to results obtained earlier (Figure 3).

The fatty acid-containing media had a significant effect on the sustained plateau in cytosolic Ca\(^{2+}\) following stimulation with BK \((p<0.001)\), as shown in Figure 8B. Analysis of variance of the steady state data showed no significant effect of TNF in this system in either control or diabetic fibroblasts, probably due to BSA in the media.

**Discussion**

Human skin fibroblasts from type 1 diabetic subjects exhibit several distinguishing features that differentiate them from control fibroblasts. These include an altered sensitivity to cytokines that results in greatly enhanced Ca\(^{2+}\) responses to BK and fatty acids. They also have a small but significantly lower basal Ca\(^{2+}\) that normalizes in response to cytokines. These features join several published studies documenting other differences between control and type 1 diabetic fibroblasts \([44–46]\) and suggest possible additional markers of disease susceptibility that may be useful in applying preventive strategies to susceptible individuals \([47]\).

The mechanism by which both TNF and a high fatty acid environment increase the peak Ca\(^{2+}\) response and steady state Ca\(^{2+}\) level following stimulation with BK is not known. These findings could have many separate causes, but also can be linked together in a simple speculative model (Figure 9) centered around cytosolic long chain (LC)-CoA. The model proposes that fibroblasts from type 1 diabetics are prone to greater elevation in cytosolic LC-CoA in response to cytokines or excess fatty acid. It has previously been shown that fibroblasts from people with diabetes incorporate more oleate into complex lipids than controls \([46]\). In addition, LC-CoA, the precursor for complex lipid formation, also directly stimulates Ca\(^{2+}\) uptake by the ER Ca\(^{2+}\)-ATPase and increases Ca\(^{2+}\) stores \([21]\). Since TNF and IL-1\(\beta\) inhibit mitochondrial \(\beta\)-oxidation of free fatty acids \([48]\), this would cause an increase in cytosolic LC-CoA and hence the size of the BK mobilizable Ca\(^{2+}\) stores. Fatty acids, by direct conversion to LC-CoA, also increase cytosolic long chain acyl CoA levels, increased Ca\(^{2+}\) stores, and enhanced BK response potentially by the same mechanism.

LC-CoA also has other modulatory roles in signal transduction including activation of PKC isoforms. PKC is known to play a role in TNF-induced signal transduction \([13,49]\), and we showed that calphostin C, which inhibits PKC by blocking the diacylglycerol binding site, effectively blocked the TNF-induced increment (data not shown). This suggested that PKC activity was necessary to observe a TNF-induced increment in BK response. In this model LC-CoA is the common signal that alters cytosolic Ca\(^{2+}\) stores via a direct effect on Ca\(^{2+}\)-ATPase of the ER \([21]\) and through activation of PKC. This could be linked to the reported abnormality in expression of FABP5 \([44]\) that has been found in monocytes from type 1 diabetic subjects that may increase fatty acid availability in the cytosol for LC-CoA formation.

**Comparison of the Effect of TNF Treatment of Diabetics, Non-diabetic Siblings, and Control Donors**

Analysis of the TNF-induced increment in peak BK response in all the donors surveyed (Fig 4) showed that they could be divided into 3 groups based on the level to which their fibroblasts responded to the TNF treatment. All but one of the control donors exhibited a TNF-induced increment between 200 nM and 300 nM calcium, while all but one of the diabetic donors exhibited an increment greater than 300 nM. Similarly, fibroblasts from only one control donor showed a Ca\(^{2+}\) increment greater than 200 nM. This artificial separation into three groups, according to the response of the cells to TNF treatment, suggests a genetic or epigenetic component. Studies currently underway will rederive the type 1 diabetic fibroblasts to determine if the characteristics are retained or lost following removal of the epigenetic changes \([50]\).

Type 1 diabetics comprise a very small percentage of the general population, probably not greater than 1% \([51]\), and 10 randomly selected type 1 diabetic fibroblast donors all exhibited greater effects of TNF than matched control donors. A trait present in 100% of such a small population may also occur with some frequency in the general population. If the cause of diabetes requires a combination of different factors, this can explain why two siblings who both carry a “diabetes gene” can be discordant for the disease. On the other hand, a person who does not carry the TNF-hypersensitivity trait may not become diabetic, whether or not exogenous stimuli such as a systemic viral infection occurs.

**Implications for Type 1 Diabetes**

The data presented here indicate that fibroblasts from patients with type 1 diabetic display an altered response to BK in the presence of TNF and fatty acid. Together with data documenting elevated cytokines and free fatty acids in people with type 1 diabetes \([2–4,17]\), the results herein suggest that TNF and FFA may play a role in the etiology of many of the unique pathologies associated with diabetes ranging from autoimmunity to refractory wound healing. These two factors together, high cytokines and circulating fat, have an abnormal effect in cells from patients with type 1 diabetes who are much more sensitive than controls. Determination of this trait before development of diabetes could help to identify susceptible individuals prior to disease onset. Strategies to diminish this hypersensitivity or exaggerated Ca\(^{2+}\) signal transduction could lead to improved outcomes.

**Author Contributions**

Conceived and designed the experiments: NRH BEC. Performed the experiments: NRH ARJ. Analyzed the data: NRH ARJ ALS BEC. Wrote the paper: NRH ARJ ALS BEC.
References

1. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, et al. (2005) Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54 Suppl 2: R87–107.

2. Hussain MJ, Peckman M, Gallati H, Lo SS, Hawa M, et al. (1996) Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia 39: 60–69.

3. Espersen GT, Mathiesen O, Grunnet N, Jensen S, Ditzel J (1993) Cytokine plasma levels and lymphocyte subset in patients with newly diagnosed insulin-dependent (type 1) diabetes mellitus before and following initial insulin treatment. Apmis 101: 703–706.

4. Chousich N, Rockett E, Harrison LC (1994) Endogenous TNF production differs between high and low diabetes incidence non-obese diabetic (NOD) mice. Autoimmunity 18: 163–168.

5. Cummins N, Badley A (2009) The TRAIL to viral pathogenesis: the good, the bad and the ugly. Curr Med Res Opin 25: 495–505.

6. Campbell IL, Harrison LC (1989) Viruses and cytokines: evidence for multiple roles in pancreatic beta cell destruction in type 1 insulin-dependent diabetes mellitus. J Cell Biochem 40: 57–66.

7. Melo V, Hau W, Brooks-Worrell BM, Palmer JP (1993) The functional state of the beta cell modulates IL-1 and TNF-induced cytotoxicity. Lymphokine Cytokine Res 12: 233–239.

8. Harrison LC, Campbell IL, Allison J, Miller JP (1989) MHC molecules and beta-cell destruction. Immune and nonimmune mechanisms. Diabetes 38: 815–819.

9. Coopisters KT, Boettler T, von Herrath M (2012) Virus infections in type 1 diabetes. Cold Spring Harb Perspect Med 2: a007682.

10. Filippi CM, von Herrath MG (2008) Viral trigger for type 1 diabetes: pros and cons. Diabetes 57: 2693–2697.

11. Tracey KJ, Ceresa A (1995) Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 45: 491–505.

12. Kuno K, Matsuoka K (1994) The IL-1 receptor signaling pathway. J Leukos Biol 56: 542–547.

13. Schutze S, Macleird T, Kronke M (1994) The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction. J Leukos Biol 56: 533–541.

14. Schutze S, Wiegmann K, Macleird T, Kronke M (1995) TNF-induced activation of NF kappa B. Immunobiology 193: 193–203.

15. Schutze S, Berck D, Toming O, Unger C, Kronke M (1994) Tumor necrosis factor induces rapid production of 1,2-diacylglycerol by a phosphatidylinositol-specific phospholipase C. J Exp Med 174: 975–988.

16. Guy GR, Chua SP, Wong NS, Ng SB, Tan YH (1991) Interleukin 1 and tumor necrosis factor activate common multiple protein kinases in human fibroblasts. J Biol Chem 266: 14134–14152.

17. Azad K, Parkin JM, Court S, Laker MF, Alberti KG (1994) Circulating lipids and glyceremic control in insulin dependent diabetic children. Arch Dis Child 71: 108–113.

18. Bolinder J, Stjohanger A, Arner P (1996) Stimulation of adipose tissue lipolysis and glycaemic control in insulin dependent diabetic children. Arch Dis Child 71: 108–113.

19. Bassi A, Avogaro A, Crepaldi C, Pavan P, Zambon S, et al. (1996) Short-term acidification of rat hepatocytes: synergy among TNF, IL-6, and IL-1. Diabetes 45: 233–240.

20. Yaney GC, Korchak HM, Corkey BE (2000) Long-chain acyl CoA regulation of protein kinase C and fatty acid potentiation of glucostimulated insulin secretion in clonal beta-cells. Endocrinology 141: 1989–1988.

21. Brun T, Assimacopoulos-Jeannet F, Corkey BE, Pretuki M (1997) Long-chain fatty acids inhibit acetyl-CoA carboxylase gene expression in the pancreatic beta-cell line INS-1. Diabetes 46: 393–400.

22. Yaney GC, Korchak HM, Corkey BE (2000) Long-chain acyl CoA regulation of protein kinase C and fatty acid potentiation of glucostimulated insulin secretion in clonal beta-cells. Endocrinology 141: 1989–1988.

23. Prentki M, Corkey BE (1996) Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 45: 273–287.

24. Tang C, Naassan AE, Chamous-Reig A, Koulajian K, Goh TT, et al. (2013) Susceptibility to fatty acid-induced beta-cell dysfunction is enhanced in prediabetic diabetes-prone biobreeding rats: a potential link between beta-cell lipotoxicity and diet inflammation. Endocrinology 154: 89–101.

25. Grunfeld C, Verdier JA, Nesse R, Moser AH, Feingold KR (1998) Mechanisms by which tumor necrosis factor stimulates hepatic fatty acid synthesis in vivo. J Lipid Res 29: 1327–1335.

26. Feingold KR, Grunfeld C (1987) Tumor necrosis factor alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 80: 184–190.

27. Feingold KR, Serio MK, Adi S, Moser AH, Grunfeld C (1989) Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology 124: 2336–2342.

28. Kilpatrick LE, Polin RA, Douglas SD, Corkey BE (1989) Hepatic metabolic alterations in rats treated with low-dose endotoxin and aspirin: an animal model of Reye’s syndrome. Metabolism 38: 73–77.

29. DellaPura R, Gallicchio VS (1996) The regulation of phospholipase-A2 (PLA-2) by cytokines expressing hematopoietic growth-stimulating properties. Prog Exp Biol Med 212: 174–184.

30. Gustafson-Svard C, Tageson C, Boll RM, Kald B (1993) Tumor necrosis factor-alpha potentiates phospholipase A2-stimulated release and metabolism of arachidonic acid in cultured intestinal epithelial cells (INT 407). Scand J Gastroenterol 28: 323–330.

31. Bathon JM, Croghan JC, MacGlashan DW Jr, Proustad D (1994) Bradykinin is a potent and relatively selective stimus for cytosolic calcium elevation in human synovial cells. J Immunol 153: 2600–2608.

32. Burkh RM (1992) Bradykinin signal transduction in fibroblasts. Agents Actions Suppl 38 (Pt 2): 87–92.

33. Burkh RM, Kyle DJ (1992) Recent developments in the understanding of bradykinin receptors. Life Sci 50: 829–833.

34. Lerner UH, Bruunius G, Anduren I, Berggren PO, Juntti-Berggren L, et al. (1992) Bradykinin induces a B2 receptor-mediated calcium signal linked to prostaglandin formation in human gingival fibroblasts in vitro. Agents Actions 37: 44–52.

35. O’Neill LA, Lewis GP (1989) Interleukin-1 potentiates bradykinin- and TNF alpha-induced PGE2 release. Eur J Pharmacol 166: 131–137.

36. Mony PN, Dyer A, Atkinson C, Bridle R, Welle S, et al. (2000) Association of the 5'-flanking region of the human beta-cell-stimulating hormone gene with type 1 diabetes. Diabetes 49: 523–527.

37. Lerner UH, Bruunius G, Anduren I, Berggren PO, Juntti-Berggren L, et al. (1992) Bradykinin induces a B2 receptor-mediated calcium signal linked to prostaglandin formation in human gingival fibroblasts in vitro. Agents Actions 37: 44–52.

38. O’Neill LA, Lewis GP (1989) Interleukin-1 potentiates bradykinin- and TNF alpha-induced PGE2 release. Eur J Pharmacol 166: 131–137.

39. Mony PN, Dyer A, Atkinson C, Bridle R, Welle S, et al. (2000) Association of the 5'-flanking region of the human beta-cell-stimulating hormone gene with type 1 diabetes. Diabetes 49: 523–527.

40. Mony PN, Dyer A, Atkinson C, Bridle R, Welle S, et al. (2000) Association of the 5'-flanking region of the human beta-cell-stimulating hormone gene with type 1 diabetes. Diabetes 49: 523–527.

41. Mony PN, Dyer A, Atkinson C, Bridle R, Welle S, et al. (2000) Association of the 5'-flanking region of the human beta-cell-stimulating hormone gene with type 1 diabetes. Diabetes 49: 523–527.

42. Mony PN, Dyer A, Atkinson C, Bridle R, Welle S, et al. (2000) Association of the 5'-flanking region of the human beta-cell-stimulating hormone gene with type 1 diabetes. Diabetes 49: 523–527.

43. Mony PN, Dyer A, Atkinson C, Bridle R, Welle S, et al. (2000) Association of the 5'-flanking region of the human beta-cell-stimulating hormone gene with type 1 diabetes. Diabetes 49: 523–527.